Cytokinetics Incorporated (CYTK)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News
Aficamten Treatment for 48 Weeks Shows Promising Results in Hypertrophic Cardiomyopathy Patients
Cytokinetics Allocates $100,000 in Annual Communications Grant to Boost Patient Advocacy Outreach
Cytokinetics Incorporated shows promising signs of growth with reduced losses in fiscal year 2023
Cytokinetics Incorporated announced very difficult period, during the second quarter of 2023
Cytokinetics Incorporated*s Revenue Surges, but Elusive Profitability Remains a Challenge